Cifras calculadas a partir de notificaciones regulatorias oficiales — .
Analistasobjetivo 153.06 USD (+184%) · consenso 4.89/5 · 9 compra · 0 mantener · 0 venta
Propiedadiniciados 11.94% · instituciones 94.95% · posiciones cortas 11.6% del flotante
En USD · a Oct 19, 2026
Pregúntale a la máquina
Busca y compara operaciones de iniciados, sociedades y sus estadísticas en lenguaje natural. Tu pregunta se convierte en una consulta sobre los datos disponibles, no en una conversación ni en asesoramiento de inversión.
Solo datos de BRIGHT MINDS BIOSCIENCES INC.. Sin búsqueda web. Se excluyen las estadísticas globales de cada iniciado.
Una búsqueda ejecutada consume un crédito, incluso sin resultados. Los errores y las preguntas no compatibles no consumen créditos.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Fuente de información de mercado · Oct 19, 2026
Identidad según la SEC · Oct 19, 2026
Cronología en el mercado · historial completo
12 compras1 venta— precio de cierrebarra = volumen usd, escala √haz clic en un periodo para filtrar la tabla
| Iniciado | Tipo | Valor · USD | Señales | Detalle |
|---|---|---|---|---|
| Cormorant Asset Management, LPhistorial | Venta | $9.8M | SEC |
| Cormorant Asset Management, LPhistorial | Compra | $4M | conv 33 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $374K | conv 24 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $78.4K | conv 20 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $22.9K | conv 20 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $214.1K | conv 22 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $25K | conv 20 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $1.1M | conv 37 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $65.1K | conv 21 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $171.8K | conv 20 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $922.8K | conv 21 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $56.9K | conv 20 | SEC |
| Cormorant Global Healthcare Master Fund, LPhistorial | Compra | $224.7K | conv 21 | SEC |